Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current progress in tuberculosis vaccine development.

Ian M Orme1

  • 1Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA. ian.orme@colostate.edu

Vaccine
|March 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis.

Vaccine·2020
Same author

Trying to See the Forest through the Trees: Deciphering the Nature of Memory Immunity to <i>Mycobacterium tuberculosis</i>.

Frontiers in immunology·2018
Same author

Biology of clinical strains of Mycobacterium tuberculosis with varying levels of transmission.

Tuberculosis (Edinburgh, Scotland)·2018
Same author

GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.

Clinical and vaccine immunology : CVI·2017
Same author

Pillars Article: The Kinetics of Emergence and Loss of Mediator T Lymphocytes Acquired in Response to Infection with <i>Mycobacterium Tuberculosis</i>. <i>J. Immunol</i>. 1987. 138: 293-298.

Journal of immunology (Baltimore, Md. : 1950)·2017
Same author

Mouse and Guinea Pig Models of Tuberculosis.

Microbiology spectrum·2016
Same journal

Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" [Vaccine 82 (2026) 128588].

Vaccine·2026
Same journal

Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR.

Vaccine·2026
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
See all related articles

The tuberculosis vaccine field is rapidly advancing with over 100 new candidates. Promising results are emerging from BCG boosting and novel prime/boost protocols for tuberculosis vaccine development.

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • The field of tuberculosis (TB) vaccine development has seen significant growth over the last decade.
  • Numerous novel vaccine candidates are undergoing preclinical and clinical evaluation.
  • Existing TB vaccines, like BCG, have limitations, necessitating new approaches.

Purpose of the Study:

  • To review current animal screening models for TB vaccine candidates.
  • To discuss the diverse types of novel TB vaccines being developed.
  • To highlight promising new strategies in TB vaccine research.

Main Methods:

  • Review of existing literature on TB vaccine candidates and screening models.
  • Discussion of various vaccine platforms and prime/boost strategies.

Related Experiment Videos

  • Exploration of advanced immunological readouts and imaging techniques.

    • Main Results:

    • Over 100 new TB vaccine candidates are in development, with many in animal testing.
    • Several candidates are entering or approaching clinical trials.
    • BCG boosting and prime/boost protocols show significant promise.

    Conclusions:

    • The TB vaccine landscape is dynamic, with substantial progress in candidate development.
    • Advanced screening models and immunopathology insights are crucial for future acceleration.
    • Novel approaches, particularly BCG-based strategies, offer hope for effective TB vaccines.